ArticleOpen forum infectious diseases2025
Role of Giannella and Increment Scores to Predict OXA-48 Carbapenemase Producing Enterobacterales Infection and Mortality in Previous Rectal Carriers.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical, Microbiological and Genomic Characterization of OXA-48-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- When might we consider using the newer β-lactam agents as empirical therapy against presumed carbapenem-resistant gram-negative infections?JAC-antimicrobial resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To assess the ability of Giannella Risk Score (GRS), Increment Score (IS), and modified-Increment Score (m-IS) to predict the risk of infection after colonization by OXA-48 producing Enterobacterales (OXA-48-Ent) and mortality after infection. Methods: A retrospective cohort study (2020-2022) including 273 patients colonized with OXA-48-Ent. univariable and multivariable analysis to identify predictors for OXA-48-Ent infection at 30 days after colonization and 30-day mortality among infection episodes, including GRS, IS, and m-IS, were performed. Results: Fifty-seven (20.1%) patients developed an infection during the first year after colonization, with 51 (90%) of 66 infection episodes occurring within the first 30 days. Seventeen (7.8%) of 219 patients with a GRS < 7 developed an infection whereas this occurred in 34 (63%) of 54 with a GRS ≥ 7 ( Conclusions: A significant proportion of patients colonized by OXA-48-Ent develop infection by its colonizing strain within the first 30 days after colonization. The application of GRS, IS, and m-IS identified OXA-48-Ent colonized patients with a low risk for infection and with low risk of mortality in the case of a confirmed OXA-48-Ent infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.